Shares of HEALTHYWAY INC (02587) climbed more than 6% following the release of its interim results, trading at HK$1.81 at the time of writing, a gain of 6.18%, with turnover reaching HK$9.40 million.

On August 28, the company announced its interim results for the six months ended June 30, 2026. Group revenue reached RMB 775 million, marking a year-on-year increase of 49.72%. Profit attributable to equity shareholders stood at RMB 9.161 million, an increase of 29.65% year-on-year, with basic earnings per share of RMB 0.01.

Recently, the company released a supplementary announcement detailing a strategic reallocation of approximately HK$107 million of unused IPO proceeds. Funds originally earmarked for expanding offline pharmacies, large-scale recruitment of on-site health assistants, and business development representatives have now been redirected toward AI agent technology research and regional ecosystem expansion.

Notably, this increased focus on AI is not mere concept hype. The company's related business segments have achieved consecutive, tangible implementations, with a clear and verifiable commercialization path already established.